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Abstract 1 
Background: Although a large number of randomized controlled trials (RCTs) have 2 
examined the impact of the n-3 (ω-3) fatty acids EPA (20:5n-3) and DHA (22:6n-3) on blood 3 
pressure and vascular function, the majority have used doses of EPA+DHA of > 3 g per d, 4 
which are unlikely to be achieved by diet manipulation.  5 
Objective: The objective was to examine, using a retrospective analysis from a multi-center 6 
RCT, the impact of recommended, dietary achievable EPA+DHA intakes on systolic and 7 
diastolic blood pressure and microvascular function in UK adults.  8 
Design: Healthy men and women (n = 312) completed a double-blind, placebo-controlled 9 
RCT consuming control oil, or fish oil providing 0.7 g or 1.8 g EPA+DHA per d in random 10 
order each for 8 wk. Fasting blood pressure and microvascular function (using Laser Doppler 11 
Iontophoresis) were assessed and plasma collected for the quantification of markers of 12 
vascular function. Participants were retrospectively genotyped for the eNOS rs1799983 13 
variant. 14 
Results: No impact of n-3 fatty acid treatment or any treatment * eNOS genotype interactions 15 
were evident in the group as a whole for any of the clinical or biochemical outcomes. 16 
Assessment of response according to hypertension status at baseline indicated a significant 17 
(P=0.046) fish oil-induced reduction (mean 5 mmHg) in systolic blood pressure specifically 18 
in those with isolated systolic hypertension (n=31). No dose response was observed. 19 
Conclusions: These findings indicate that, in those with isolated systolic hypertension, daily 20 
doses of EPA+DHA as low as 0.7 g bring about clinically meaningful blood pressure 21 
reductions which, at a population level, would be associated with lower cardiovascular 22 
disease risk. Confirmation of findings in an RCT where participants are prospectively 23 
recruited on the basis of blood pressure status is required to draw definite conclusions. 24 
 25 
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Introduction 30 
Current dietary guidelines, predominantly informed  by prospective epidemiological evidence 31 
(1, 2), typically recommend a minimum intake of the marine n-3 (ω-3) fatty acids EPA 32 
(C20:5n-3) and DHA (C22:6n-3) of 0.5 g per d for healthy individuals, increasing to 1 g per d 33 
for those with diagnosed cardiovascular disease (CVD) (3, 4). The majority of published 34 
randomized controlled trials (RCTs) establishing the efficacy of EPA+DHA on 35 
cardiovascular risk factors have used daily doses of greater than 3 g per d. Such intakes 36 
cannot be achieved through diet manipulation and require use of concentrated or 37 
pharmaceutical grade supplements. Meta-analyses or systematic reviews of available RCTs 38 
indicate that such high dose (> 3 g EPA+DHA per d) n-3 fatty acid supplementation reduces 39 
systolic and diastolic blood pressure (SBP and DBP) by approximately 2-4 mmHg and 1-3 40 
mmHg, respectively (5-8) with hypertensive individuals being most responsive (5, 7). Less 41 
well explored is the impact of intakes of EPA+DHA up to 2 g per d, and in particular in the 42 
0.5 to 1.0 g per d range (commonly recommended minimum intakes), which can be achieved 43 
through the diet by consuming oily fish (9), on established CVD risk factors such as blood 44 
pressure. 45 
Loss of normal vascular function has an etiological role in hypertension and atherogenesis, 46 
and vascular reactivity of both the coronary and peripheral arteries is highly prognostic of 47 
future clinical events (10). The limited data available from adequately powered RCTs provide 48 
inconsistent evidence to indicate whether EPA+DHA can improve arterial vascular reactivity 49 
and stiffness (11, 12). While some more recent trials have used daily intervention doses in the 50 
1.5-3.0 g EPA+DHA range (12-14), the impact of lower intakes on vascular tone and overall 51 
function is poorly understood. Furthermore, the trials with vascular primary end-points have 52 
been conducted mainly in diabetic or hyperlipidemic subjects. Although at the whole 53 
population level the impact of lower intakes of EPA+DHA on blood pressure and vascular 54 
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functions may be modest, clinically relevant changes may occur in more responsive 55 
population sub-groups. Such sub-groups could be specifically targeted to increase their 56 
EPA+DHA intake in order to gain a health benefit. Here we report the impact of modest n-3 57 
fatty acid doses (0.7 and 1.8 g of EPA+DHA per d) on blood pressure and vascular function 58 
in healthy adults and investigate the influence of sex, baseline EPA+DHA and hypertensive 59 
status, and endothelial nitric oxide synthase (eNOS) genotype on response to n-3 fatty acid 60 
treatment. We focused on the eNOSGlu298Asp polymorphism (rs1799983) because of its 61 
reported impact on vascular function and cardiovascular risk (15) along with a previous 62 
observation of an influence of this variant on the association between vasodilation and plasma 63 
EPA+DHA concentrations (16), and more recently the acute vasodilatory response to 64 
EPA+DHA intake (17). 65 
 66 
Methods  67 
Subjects and Study Design   68 
The aim of the FINGEN Study (Glasgow, Newcastle, Reading and Southampton 69 
Universities) was to investigate the responsiveness of a range of established and putative 70 
markers of CVD risk to modest dose fish oil intervention. Participants were prospectively 71 
recruited on the basis of apo E (APOE) genotype, sex and age to ensure equal numbers of 72 
APOE2 and APOE4 carriers and APOE3/E3 homozygotes, males and females and spread of 73 
age across the five decades 20-70 y. This stratification was undertaken to provide sufficient 74 
group size and hence power to establish the impact of these variables on response to 75 
treatment. Details of the study design and subject characteristics have been published (18). In 76 
brief, healthy subjects (n = 364, aged 18-70 y, BMI 18.5 to 30 kg/m2) were recruited 77 
according to defined inclusion/exclusion criteria (see Supplemental Methods). Blood 78 
pressure elevation or anti-hypertensive medication use was not an exclusion criterion. The 79 
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study was approved by the local research ethics committees and all subjects provided 80 
informed written consent prior to participation (18). The trial adhered to the principles of the 81 
Declaration of Helsinki. 82 
 83 
Intervention 84 
The study was a double-blind placebo-controlled, dose-response, cross-over study, consisting 85 
of 3 intervention arms each of 8-wk duration. A wash-out period of 12-wk was observed 86 
between intervention arms (18). During the intervention periods participants consumed in 87 
random order, either 3.2 g of the control oil (CO), 3.2 g fish oil (FO) providing 1.8 g 88 
EPA+DHA/d (1.8FO) or a 50:50 CO:FO blend providing 0.7 g EPA+DHA/d (0.7FO). The 89 
CO was an 80:20 mixture of palm oil and soybean oil. The ratio of DHA to EPA in the FO 90 
was 1.4, which approximates the ratio found in marine sources and therefore in the habitual 91 
diet (19, 20). Additionally, participants consumed a low fat meal (< 10 g fat) the evening 92 
before each assessment visit. 93 
 94 
Blood Pressure and Vascular Measurements 95 
Blood pressure (BP) measurements were taken at rest (≥ 5 min) on the non-dominant arm, 96 
which was elevated to heart level, using an automated BP device (Omron Model 705IT, 97 
Milton Keynes, UK). After measuring the upper arm circumference, an appropriately sized 98 
cuff (pneumatic bag 20% wider than the upper arm circumference) was used. Blood pressure 99 
measurements were taken until two consecutive readings were within 10 mmHg for both 100 
systolic BP (SBP) and diastolic BP (DBP). The average of these two stable readings was used 101 
for data analysis. Measurements were performed by fully trained research staff, in accordance 102 
with a multi-center accepted standard operating procedure.   103 
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At two of the intervention sites, Reading and Glasgow (n=177), the vascular reactivity of the 104 
cutaneous microvasculature on the volar aspect of the forearm was determined by Laser 105 
Doppler Iontophoresis (LDI) (21). As vascular reactivity is dependent on ambient 106 
temperature and activity levels, all participants were acclimatized at rest in a temperature 107 
controlled room for 30 minutes prior to LDI assessment. Sodium nitroprusside (SNP, 1% 108 
solution) and acetylcholine (ACh, 1% solution) were used as endothelial independent and 109 
dependent vasodilators, respectively. SNP and ACh were applied to the iontophoresis 110 
chambers on the forearm and delivered transdermally using an incremental current 0-20 μA. 111 
The response of the dermal circulation was measured by Laser Doppler imaging (Moor 112 
Instrument Ltd, Axminster, UK), whereby a backscattered light which experiences a Doppler 113 
shift imparted by moving red cells in the underlying circulation was collected in a series of 20 114 
scans and used to determine blood flow. Results are expressed as area under the curve (AUC) 115 
or incremental AUC (IAUC) of the 20 scans recorded or flux according to cumulative charge. 116 
 117 
Biochemical Analysis and Genotyping 118 
Fasting blood was drawn into lithium heparin for assessment of NO availability, endothelin-1 119 
(ET-1), adhesion molecules and phosphatidylcholine (PC) fatty acids, with plasma stored in 120 
individual vials at -80°C. NO and ET-1 are key endothelial-derived vasodilatory and 121 
vasoconstrictive agents, respectively (22, 23). NO is labile and cannot be quantified directly; 122 
therefore plasma levels of nitrite+nitrate, which serve as a biomarker of NO availability, 123 
where determined. Total plasma nitrite+nitrate was measured using a commercial kit (R&D 124 
Systems Europe, Abingdon, UK). ET-1 concentrations were analyzed using a Quantiglow 125 
human ET-1 immunoassay kit (R&D Systems Europe, Abingdon, UK). The soluble adhesion 126 
molecules quantified using ELISA, included vascular cell adhesion molecule-1 (VCAM-1), 127 
intercellular adhesion molecule-1 (ICAM-1), P-selectin and E-selectin (all kits sourced from 128 
 The Journal of Nutrition NUTRITION/2015/220475 Version 4
9 
 
BioSource Europe, Nivelles, Belgium). These molecules, expressed on the surface of 129 
endothelial cells, modulate leukocyte recruitment into the sub-endothelial space and 130 
contribute to a pro-inflammatory state and overall vascular dysfunction (24). The fatty acid 131 
composition of the plasma PC fraction was determined using previously described methods 132 
(25), with lipid extraction, PC isolation using solid phase extraction, transmethylation and 133 
methyl ester separation by gas phase chromatography being the principal steps involved. 134 
eNOS genotype (rs1799983) was determined using a TaqMan (Assay-on-demand) SNP 135 
Genotyping kit (Applied Biosystems, Warrington, UK). 136 
 137 
Statistical Analysis 138 
A repeated-measures analysis was performed to test for a treatment effect, with baseline 139 
values and period (order of intervention) as covariates. Participants were treated as fixed 140 
effects, as the use of random effect models introduces the potential for cross-level bias (26). 141 
No treatment carry-over effect was evident. Subgroup responses according to sex, eNOS 142 
genotype, and tertile of baseline EPA+DHA status were tested by including an interaction 143 
term between the group and treatment in the model. For the main vascular and blood pressure 144 
measures, an additional analysis was conducted in normotensives (NT) vs. hypertensives 145 
((HT); SBP and DBP of ≥ 140 and/or ≥ 90 mmHg) and normotensives vs. dual HTs ((DHT); 146 
SBP and DBP of  ≥ 140 and ≥ 90 mmHg) vs. isolated systolic hypertensives ((SHT); SBP ≥ 147 
140 and DPB < 90 mmHg)(27). The current analysis represented a retrospective secondary 148 
analysis of the FINGEN cohort, with the primary study end-point, and the basis of the 149 
original power calculations, being plasma triglycerides and LDL-cholesterol. The inclusion of 150 
312 subjects in a cross-over design, provided > 99% power to detect a 6 mmHg reduction in 151 
SBP and a 4 mmHg reduction in DBP between any two treatments in the group as a whole. 152 
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All analyses were conducted using SAS Version 9.1 (Cary, US) and SPSS Version 15 153 
(Chicago, US), and P<0.05 was considered to indicate statistical significance. 154 
 155 
Results 156 
A total of 312 subjects, including 163 females and 149 males, completed the study (the 157 
CONSORT flow diagram is Supplemental Figure 1 (18)). They had a mean ± SD age of 158 
45.0 ± 13.0 years and BMI of 25.2 ±  3.4 kg/m2, and 6% of subjects were taking anti-159 
hypertensive medication. 160 
Expressed as absolute % of total fatty acids relative to the control oil, 0.7FO and 1.8FO 161 
increased plasma PC EPA by 1.3 and 2.2 respectively, with increases of 2.1 and 2.5 for DHA 162 
(Table 1, all P<0.001). As we have reported previously (18), a significant sex * treatment 163 
interaction was evident with greater enrichment of PC EPA+DHA in females than in males, 164 
possibly attributable to the higher n-3 fatty acid dose per unit body weight. 165 
 For the participants as a whole, the intervention had no effect on BP, vascular function or 166 
any of the biochemical measures included and there was no evidence of any sex * treatment 167 
or baseline EPA+DHA status * treatment interactions (Table 1).  168 
However, a total of 48 subjects were classified as HT; of these 17 were classified as DHT and 169 
31 as SHT (27).  HTs were older and had higher BMI than NTs (both P<0.001) (Table 2). 170 
Mean ± SD baseline SBP and DBP (mmHg) of 118.6 ± 14.0 and 73.0 ± 8.5, 156.8 ± 19.1 and 171 
98.4 ± 10.0, and 145.8 ± 10.5 and 81.1 ±  5.4 were found in NTs, DHTs and SHTs, 172 
respectively. A significant treatment * hypertension status interaction was observed (P=0.022) 173 
with a significant reduction in blood pressure following intervention only for those with SHT 174 
(Figure 1a). Relative to CO, 0.7FO and 1.8FO resulted in a mean (95% CI) difference of -175 
5.20 (-9.23, -1.18) and -5.31 (-9.45, -1.18) mmHg in SBP respectively, with no significant 176 
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differences between the treatment groups and no treatment * BP status interaction evident for 177 
DBP. 178 
HT status was also associated with a differential DHA response (Figure 1b) (P=0.044) with 179 
evidence of greater increases in the SHT group. Older age has been associated with greater n-180 
3 fatty acid accumulation following supplementation (28), so that the greater DHA response 181 
in HTs may reflect the fact that HTs were on average a decade older than the NT group. 182 
eNOS genotypic distributions were in Hardy-Weinberg equilibrium with the frequency of 183 
Glu298Glu (48%), Glu298Asp (42%), Asp298Asp (10%) being similar to that observed in 184 
previous studies in Caucasians (16, 29). eNOS genotype was not a significant determinant of 185 
BP or vascular measures or of their response to EPA+DHA intervention (Table 3). 186 
 187 
Discussion 188 
Our main finding is that intakes of EPA+DHA achievable through the consumption of two to 189 
three portions of oily fish per wk, or two fish oil capsules per d, reduced SBP by 5 mmHg in 190 
those with SHT. Such BP reduction would be associated with an approximate 20% reduction 191 
in CVD risk in middle age (30).  192 
In the UK and the US about 30% of adults have high blood pressure (defined as being 193 
hypertensive or being treated with anti-hypertensive medications) (31, 32). In those without 194 
relevant co-morbidities the threshold for drug treatment is a sustained SBP ≥ 160 mmHg 195 
and/or a DBP ≥ 100 mg Hg (33). As a result, in the UK, about half of male and a third of 196 
female hypertensives remain untreated despite compelling evidence of continuous 197 
associations between usual blood-pressure values down to 115 mmHg (systolic) and 75 198 
mmHg (diastolic) and the risks of major cardiovascular diseases (34). Our data suggest that 199 
increased long chain n-3 PUFA intakes (of only 0.7 g per d, providing approximately 0.3 g 200 
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EPA and 0.4 g of DHA) may be an effective strategy for BP control in this large population 201 
subgroup.  202 
The size effect from supplementation with n-3 fatty acids (5 mmHg) is largely consistent with 203 
that reported in previous meta-analyses with Morris et al. (8), Appel et al. (35), Geleijnse et 204 
al. (6) and Miller et al. (7) observing reductions of SBP in hypertensives of 3.4, 5.5, 4.0, and 205 
4.5 mmHg, respectively. However, importantly, the current RCT used daily intakes of 206 
EPA+DHA which were 40-90% lower than the mean/median intakes of studies reported in 207 
these meta-analyses (3-5 g EPA+DHA per d), indicating that in SHT individuals lower doses 208 
are sufficient to induce a substantial benefit. In the most recent meta-analysis of Miller et al. 209 
(7) which included 70 RCTs with a mean EPA+DHA dose of 3.8 g per d, twenty studies used 210 
doses of fish oil which provided < 2 g EPA+DHA per d. Of these, only two examined 211 
response to treatment in hypertensive subjects (36, 37). Although both these studies reported 212 
no significant impact on SBP, mean reductions of 5 mmHg were evident in both and it seems 213 
likely that a lack of significance in these two previous studies was due to a lack of power, 214 
rather than lack of a real biological impact (these studies had 17 (36) and 23 (37) individuals 215 
in the fish oil groups, respectively).  216 
It is possible that the high DHA: EPA ratio in the supplement may have contributed to the 217 
relatively large effect size in the current study. Previous RCTs which compared the anti-218 
hypertensive action of EPA vs DHA rich supplements indicated a greater effect of the latter 219 
(38, 39). For example in overweight men supplemented for 6 wk, 4 g of DHA per d, but not 220 
EPA, reduced 24 h and d time ambulatory blood pressure (39). Also, consistent with a lack of 221 
dose response previously reported (5, 7) we observed a similar 5 mmHg reduction in SBP 222 
following both n-3 fatty acid supplementation doses, which may indicate that the maximum 223 
physiological impact is already achieved at the lower intake (0.7 g EPA+DHA per d). 224 
Alternatively, the lack of dose response may reflect the only modestly higher plasma DHA 225 
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status achieved at the higher level of supplementation, despite a more than doubling of intake, 226 
with 42% and 58% increased plasma DHA following the 0.7FO and 1.8FO, respectively. This 227 
lack of accrual at higher doses may be attributable to the known increase in β-oxidation of 228 
DHA at higher intakes (40).  229 
The anti-hypertensive effects of EPA and DHA are likely to be due to multiple mechanisms 230 
and to include impacts on heart rate and cardiac output along with improved endothelial and 231 
overall vascular function (14, 41-44). Previously reported mechanisms underlying the 232 
vascular effects, include an increased production of EPA and DHA derived vasoactive 233 
eicosanoids and epoxides, enhanced bioavailability of nitric oxide, and reduced adhesion 234 
molecule expression associated with improved inflammatory status (25, 43, 45, 46). No 235 
impact of treatment on plasma adhesion molecule concentrations was evident in the current 236 
study which is consistent with what has been seen in several other studies using modest doses 237 
of EPA+DHA (46, 47) so that the efficacy of the supplement used in our study is unlikely to 238 
be mediated by changes in adhesion molecule expression in the endothelium.  239 
Furthermore no impact of treatment on (micro) vascular function as determined by LDI was 240 
evident. The cutaneous vasculature represents an accessible and representative vascular bed 241 
for the establishment of treatment effects on vascular function and specifically NO mediated 242 
vasodilation (48). Although an impact of fish oil supplementation on postprandial 243 
microvascular reactivity has been demonstrated by us and others (14, 17, 49), consistent with 244 
the findings of Stirban et al. (14) and Skulas-Ray et al. (50), no effect of chronic EPA+DHA 245 
supplementation on fasting vasodilation was evident in the current study. However, this does 246 
not preclude an impact of treatment on macrovascular function. Large conduit artery (e.g. 247 
aorta) stiffening, associated with elastin fragmentation and neuro-hormonal alterations in the 248 
vascular wall, and the wave-reflection phenomenon, have been identified as being the most 249 
important pathophysiological determinants of age-related increases in SHT and pulse 250 
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pressure (51, 52). Carotid-femoral artery pulse wave velocity (cf-PWV), which increases with 251 
increasing stiffness is the gold standard measure of arterial stiffness. In a 2011 meta-analysis, 252 
Pase et al. (41) showed an overall beneficial impact of EPA+DHA on PWV which has been 253 
confirmed in more recent RCTs (42). The impact of modest (< 2 g per d) EPA+DHA intakes 254 
on large artery compliance and stiffness in those with SHT is unknown and further 255 
exploration of this is merited. 256 
Finally, in contrast with a single previous observational study (16) and with an intervention 257 
trial (17), we observed no impact of the eNOS rs1799983 genotype on vascular or NO 258 
responses. This gene variant, which alters the amino acid at position 298 in the mature 259 
protein (Glu298Asp), has been shown to increase protein cleavage with consequent 260 
inactivation of eNOS (53), and to be associated with reduced circulating NO levels, vascular 261 
reactivity and CVD incidence (15). Lesson et al. (16) observed that this genotype influenced 262 
the association between plasma EPA+DHA status and flow-mediated brachial artery 263 
dilatation (FMD), with a significant association in 298Asp carriers but not in Glu298Glu 264 
homozygotes. Using a prospective recruitment according to eNOS genotype approach, 265 
Thompson and co-workers (17) reported a 2-fold greater EPA+DHA induced postprandial 266 
increase in FMD in Asp298Asp versus Glu298Glu males and females, with the greater LDI 267 
responsiveness in Asp homozygotes evident in females only. Neither study examined the 268 
impact of genotype on the BP response to treatment. In the current study, the lack of overall 269 
impact of this gene variant on vascular function and SBP suggests that the SBP benefits 270 
observed may be independent of NO bioavailability and NO mediated vasodilation. The 271 
limited numbers of participants precluded any analysis being conducted on potential eNOS 272 
rs1799983 genotype * treatment interaction in the SHT group. 273 
The strengths of the current study are the relatively large group size and associated power to 274 
detect subtle BP changes, the cross-over design, the dose response approach, and the use of 275 
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dietary achievable EPA+DHA intakes. Limitations include a lack of ambulatory BP data and 276 
the retrospective secondary nature of the analysis, which resulted in relatively small numbers 277 
in the HT groups relative to those in the NT group. Our prospective recruitment approach 278 
ensured a group of UK adults (20-70 y) who were balanced with respect to sex, age and 279 
APOE genotype. This however resulted in a study population which was over-represented for  280 
APOE2 and APOE4 carriers relative to a typical Caucasian population, which comprise 20-25% 281 
and 55-60% respectively (54). Carrying an APOE4 allele has been associated with a greater 282 
risk of hypertension (55). Therefore it is possible that the efficacy of intervention in SHT in 283 
the FINGEN cohort may in part reflect a greater number of APOE4 carriers relative to the 284 
general population; this group was found to be particularly responsive to the triglyceride 285 
lowering impact of n-3 fatty acid intervention (18). However given that there was a roughly 286 
equal distribution of APOE4 genotype in SHTs (42%) and NTs (36%) it is unlikely that 287 
APOE4 genotype influenced the responsiveness in the SHT group. 288 
Conclusions: Our data indicate that in those with isolated systolic hypertension, daily doses 289 
of EPA+DHA as low as 0.7 g can bring about clinically meaningful blood pressure 290 
reductions. Full confirmation of findings in an RCT where participants are prospectively 291 
recruited on the basis of BP status is suggested to draw definite conclusions, with the 292 
inclusion of a measure of conduit artery function in order to gain insight into the 293 
physiological basis of the hypotensive response. 294 
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Figure Legends 313 
Figure 1. Effect of hypertension status at baseline on the systolic blood pressure and 314 
plasma DHA response to the control and fish oil interventions (0.7 and 1.8 g EPA+DHA 315 
per d) in healthy adults.  316 
 317 
(A) Systolic blood pressure and (B) Diastolic blood pressure  318 
Data are mean difference with 95% CI, mmHg 319 
Hypertension (HT) status categorized individuals as either normotensive (Normal, n=264, SBP < 140 mmHg 320 
and DBP < 90 mmHg), dual hypertensive (DHT, n=17, SBP ≥ 140 mmHg and DBP ≥ 90 mmHg) or isolated 321 
systolic hypertensive (SHT, n=31, SBP ≥ 140 mmHg and DBP < 90 mmHg). 322 
In repeated measures analysis on end of treatment values, with baseline values and period as co-variates, a 323 
significant treatment * HT status interaction was evident for SBP (P = 0.046) and plasma DHA (P = 0.044).  324 
CO, control oil; 0.7FO, 0.7 g EPA+DHA per d; 1.8FO, 1.8 g EPA+DHA per d   325 
•   326 
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Table 1: Vascular and plasma biochemical responses to the control and two doses of fish oil for 8 wk each in healthy adults
1
  
 
 CO
2 
8 wk 
0.7FO
2 
8 wk 
1.8FO
2 
8 wk 
P, treatment
3 
P, sex * 
treatment
3 
P, HT status
4
 * 
treatment
3 
P, EPA+DHA 
status
4
 * 
treatment
3 
BMI (kg/m
2
)
 
25.2 ± 3.41,a 25.4 ± 3.4b 25.3 ± 3.5b 0.006 NS5 NS NS 
DBP, mmHg
 
75.2 ± 9.2 74.6 ± 9.2 74.9 ± 9.8 NS NS NS NS 
SBP, mmHg 
124 ± 15 123 ± 16 123 ± 16 NS NS 0.046 NS 
ACHAUC, flux units
 
1300 ± 7091 1320 ± 779 1310 ± 671 NS NS NS NS 
SNPAUC, flux units
 
1500 ± 781 1500 ± 857 1560 ± 834 NS NS NS NS 
        
Plasma PC EPA, % total FA 
1.6 ± 0.8a 2.9 ± 1b 3.8 ± 1.2c <0.001 <0.0016 0.08 (NS) NS 
Plasma PC DHA, % total FA 
4.3 ± 1.2a 6.2 ± 1.2b 6.8 ± 1.4c <0.001 NS 0.044 NS 
        
Nitrate + nitrite, μM 
102 ± 40 104 ± 40 99 ± 38 NS NS NS 0.08 (NS) 
Endothelin-1, pg/ml 
0.97 ± 0.51 0.96 ± 0.49 0.93 ± 0.44 NS NS NS NS 
sVCAM-1, ng/ml 
1920 ± 952 1830 ± 926 1860 ± 927 NS NS NS NS 
sICAM-1, ng/ml 
324 ± 135 315 ± 136 315 ± 122 NS NS NS NS 
sE-Selectin, ng/ml 
75.9 ± 39.3 76.9 ± 37.9 76.2 ± 38.2 NS NS NS 0.07 (NS) 
sP-Selectin, ng/ml 
67.4 ± 64.5 68.8 ± 76.2 68.5 ± 67.1 NS NS NS NS 
1
Data are mean ± SD, n=312 except for SNPAUC and ACHAUC where n = 161.  
2
CO- control oil; 0.7FO- 0.7 g EPA+DHA per d; 1.8FO- 1.8 g EPA+DHA per d, 
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3
To test for a treatment effect a repeated measures analysis was carried out, with baseline values and period as covariates. In order to establish response to treatment according to sex, HT 
and EPA+DHA status at baseline an interaction term between the group and treatment was included in the model, 
4
Hypertension (HT) status categorizes individuals as either normotensive (n=264, SBP < 140 mmHg and DBP < 90 mmHg), dual hypertensive (n=17, SBP ≥ 140 mmHg and DBP ≥ 90 mmHg) or 
isolated systolic hypertensive (n=31, SBP ≥ 140 mmHg and DBP < 90 mmHg): 
4
EPA+DHA status categorizes individuals in tertiles (T) according to EPA+DHA as a % of total plasma 
phosphatidylcholine fatty acids, 
5
NS is non-significant, P > 0.05, 
6
Males had significant differences relative to females for both low CO vs 0.7FO and CO vs 1.8FO, but not significantly different between 0.7FO and 1.8FO 
a,b,c 
Labelled means in a row without a common letter differ, P < 0.05, 
Abbreviations: ACHAUC- the vasodilatory response to acetylcholine, DBP-diastolic blood pressure, DPA- docosapentaenoic acid, FA- fatty acids, HT- hypertension, ICAM- intercellular adhesion 
molecule, PC- phosphatidylcholine, SBP-systolic blood pressure, SNPAUC- the vasodilatory response to sodium nitroprusside, VCAM- vascular cell adhesion molecule. 
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Table 2: Baseline characteristics of the cohort according to blood pressure status in healthy adults
1 
 NT (n=264)
2 
 
DHT (n=17)
2
 SHT (n=31)
2
 P
3 
Age, y 
43.7 ± 12.81,a 54.0 ± 5.5b 53.4 ± 13.0b <0.001 
BMI, kg/m
2
 
25.1 ± 4.8a 27.1 ± 3.1b 27.3 ± 2.7b 0.011 
Female/male 150/114 3/17 10/21 <0.001 
     
DBP, mmHg 
73.0 ± 8.5a 98.4 ± 10.0c 81.1 ± 5.4b <0.001 
SBP, mmHg 
119 ± 14a 157 ± 19c 146 ± 11b <0.001 
ACHAUC, flux units
 
1530 ± 1050 1020 ± 413 1350 ± 573 NS4 
SNPAUC, flux units
 
1720 ± 1064 1390 ± 452 1440 ± 558 NS 
     
Plasma PC EPA, % total FA 
1.6 ± 0.8 1.8 ± 0.9 1.5 ± 0.7 NS 
Plasma PC DHA, % total FA 
4.4 ± 1.2 4.6 ± 1.4 4.2 ± 1.3 NS 
     
Nitrate + nitrite, μM 
98 ± 41 107 ± 46 104 ± 35 NS 
Endothelin 1, pg/ml 
0.95 ± 0.49 1.03 ± 0.52 1.09 ± 0.59 NS 
sVCAM-1, ng/ml 
1870 ± 933 1780 ± 849 1910 ± 851 NS 
sICAM-1, ng/ml 
302 ± 132 330 ± 105 330 ± 142 NS 
sE-Selectin, ng/ml 
72.2 ± 40.0 79.2 ± 41.4 80.3 ± 27.2 NS 
sP-Selectin, ng/ml 
64.4 ± 71.4 72.6 ± 41.4 73.4 ± 102.9 NS 
1
Data are mean ± SD, n= 264, 17 and 31 for NT, DHT and SHT respectively for all variables apart from ACHAUC and SNP AUC 
where n= 142, 6 and 13 for NT, DHT and SHT respectively, 
2
Normotensive (NT), SBP < 140 mmHg and DBP < 90 mmHg; Dual hypertensive (DHT), SBP ≥ 140 mmHg and DBP ≥ 90 
mmHg; Isolated systolic hypertensive (SHT), SBP ≥ 140 mmHg and DBP < 90 mmHg, 
3
Inter-group differences were analyzed by 1-way ANOVA,  
4
NS is non-significant, P > 0.05, 
a,b,c 
Labelled means in a row without a common letter differ, P < 0.05, 
Abbreviations: ACHAUC- the vasodilatory response to acetylcholine, DBP-diastolic blood pressure, DPA- docosapentaenoic 
acid, FA- fatty acids, ICAM- intercellular adhesion molecule, PC- phosphatidylcholine, SBP-systolic blood pressure, SNPAUC- 
the vasodilatory response to sodium nitroprusside, VCAM- vascular cell adhesion molecule. 
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Table 3: Vascular and plasma nitrate plus nitrite responses to the control and two doses of fish oil 
for 8 wk each in healthy adults, according to eNOS genotype  
 CO
2 
8 wk 
0.7FO
2 
8 wk 
1.8FO
2 
8 wk 
P, treatment 
*eNOS genotype
3 
SBP, mmHg 
-Glu298Glu
 
-Glu298Asp 
-Asp298Asp 
 
123 ±  161 
123 ±  15 
127 ± 14 
 
124 ±  16 
122 ±  16 
126 ±  15 
 
124 ±  17 
122 ±  16 
126 ±  15 
NS
4 
DBP, mmHg 
-Glu298Glu
 
-Glu298Asp 
-Asp298Asp 
 
75.0 ± 9.1 
74.6 ± 9.5 
78.7 ± 7.9 
 
74.7 ±  9.3 
73.9 ±  9.1 
76.9 ±  8.6 
 
74.8 ±  9.5 
74.1 ±  10.2 
78.7 ±  9.2 
NS 
ACHAUC, flux units 
-Glu298Glu
6 
-Glu298Asp 
-Asp298Asp 
 
1290 ± 656 
1370 ± 791 
1130 ± 567 
 
1210 ±  634 
1380 ±  895 
1610 ±  818 
 
1330 ±  669 
1260 ±  656 
1400 ±  848 
NS 
SNPAUC, flux units 
-Glu298Glu
 
-Glu298Asp 
-Asp298Asp 
 
1470 ± 776 
1600 ± 833 
1270 ± 568 
 
1390 ±  738 
1590 ±  984 
1660 ±  857 
 
1590 ±  860 
1470 ±  811 
1690 ±  903 
NS 
Nitrate + nitrite, 
μM 
-Glu298Glu
6 
-Glu298Asp 
-Asp298Asp 
 
101 ±  42 
104 ± 39 
101 ± 37 
 
102 ±  40 
105 ±  39 
96 ±  35 
 
100 ±  43 
97 ±  32 
102 ±  36 
NS 
1
Data are mean ± SD, Glu298Glu, n=146, Glu298Asp, n=127 and Asp298Asp, n=30 for SBP, DBP and nitrate and nitrite; 
Glu298Glu, n=73 Glu298Asp, n=69 and Asp298Asp, n=15 for ACHAUC and SNPAUC,  
2
CO- control oil; 0.7FO- 0.7 g EPA+DHA per d; 1.8FO- 1.8 g EPA+DHA per d 
3
To test for a treatment effect a repeated measures analysis was carried out, with baseline values and period as covariates. 
In order to establish response to treatment according to eNOS genotype an interaction term was included in the model.  
4
NS is non-significant, P > 0.05, 
Abbreviations: ACHAUC- the vasodilatory response to acetylcholine, DBP-diastolic blood pressure, SBP-systolic blood 
pressure, SNPAUC- the vasodilatory response to sodium nitroprusside.  
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ONLINE SUPPORTING MATERIAL 
 
Supplemental Methods: FINGEN INCLUSION/EXCLUSION CRITERIA 
 
Inclusion criteria 
• Aged 20 to 70 y 
• APO E2/E2, E2/E3, E3/E3, E3/E4, E4/E4 
• Male or female 
• BMI 18.5-32 kg/m2 
• total cholesterol < 8.0 mM 
• TG < 3.0 mM  
• glucose < 6.8 mM. 
 
Exclusion criteria 
  APO E2/E4 
  suffered a myocardial infarction (MI) in the previous 2 years  
  chronic inflammatory conditions including inflammatory bowel disease (IBD) and 
irritable bowel syndrome (IBS) 
  diabetes or other endocrine disorders  
  pregnant, lactating or planning a pregnancy in the next 12 months 
  kidney or liver function markers outside the normal range  
  iron deficient (hemoglobin < 12 g/dL men, < 11 g/dL women)  
  on hypolipidemic medication 
  on anti-inflammatory medication  
  use of asthmatic inhalers > twice per month 
  use of aspirin > once per wk 
  on any fatty acid supplement 
For individuals on fatty acid supplements who are willing to stop taking their 
supplements, a wash-out period of 8 wk was required 
  consuming high doses of antioxidant vitamins (A, C, E, β-carotene). Maximum permitted 
intake: 800 μg/d Vitamin A, 60 mg/d Vitamin C, 10 mg/d Vitamin E and 400 μg/d β-
carotene  
For individuals on greater than the permitted dose of antioxidant vitamins and who are 
willing to stop taking their supplements, a wash-out period of 4 wk was required 
  consuming more than one serving (150 g) of oily fish per wk, which includes herring, 
mackerel, kippers, pilchards, sardines, salmon, trout, tuna (fresh), crabmeat or marlin. 
Canned tuna is permitted as it contains only minor amounts of long chain n-3 PUFAs 
  trained or endurance athletes or those who participate in more than 3 planned periods of 
exercise per wk 
  planning to lose weight by joining a weight reduction class or following an organized 
weight reducing regimen (e.g. the Slimfast Plan, Atkins Diet etc.) 
  use of Benecol or Flora Pro-Active spreads. 
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Supplemental Figure 1: Study CONSORT Flow Diagram 
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